• Wed news: Lilly’s 4.5B medicine foundry project. 5 FDA decisions to watch in Q4. Hurricane Helene and the health supply chain. Lundbeck taps Charles River for AI-enabled neuro drug discovery. Amgen tax evasion lawsuit. See more on our front page

Humira goes off patent next year

Quote

<























Anonymous said:
Don't be foolish. Start looking now...there's no place for you to go at Abbvie. S**t show if i ever saw one.
Click to expand...

With Humira facing a patent cliff and the eroding of 65% of our total revenue; the failure of VPak; the Shire fiasco; billion plus dollar break up fee maybe RG will be the fall guy. His part time CEO gig and handsome $18 mil a year salary is more than enough compensation for him to go down with the ship.
 




Not so much a patent cliff as a patent slope. Vast majority of realistic expectations have Humira in the $14-16 billion annual sales range past 2018. If H falls by half, its still a $7-8 billion drug past 2020. Not bad.
 




Anonymous said:
With Humira facing a patent cliff and the eroding of 65% of our total revenue; the failure of VPak; the Shire fiasco; billion plus dollar break up fee maybe RG will be the fall guy. His part time CEO gig and handsome $18 mil a year salary is more than enough compensation for him to go down with the ship.
Click to expand...



Wow. I guess sh#tshow really is an appropriate description of the current state of affairs. Time to dust off the old resume.
 




Anonymous said:
Not so much a patent cliff as a patent slope. Vast majority of realistic expectations have Humira in the $14-16 billion annual sales range past 2018. If H falls by half, its still a $7-8 billion drug past 2020. Not bad.
Click to expand...


Sales revenue may last a bit longer but sales reps will not. Don't delude yourself.
 




Anonymous said:
Sales revenue may last a bit longer but sales reps will not. Don't delude yourself.
Click to expand...



The race to grab market share from the world's top-selling drug is on. Indian drugmaker Zydus Cadila has launched a biosimilar of Humira in its home market--the first in a long line of in-development copies to threaten AbbVie's ($ABBV) powerhouse med.


Zydus Cadila Deputy Managing Director Sharvil Patel
The Cadila version, dubbed Exemptia, will cost a fifth of Humira's U.S. price at $200 a vial, Reuters reports. While that's still too expensive for most of India's population--70% of whom gets by on less than $2 per day--the company expects sales of between 1 billion rupees ($16.16 million) and 2 billion rupees on the Indian market, Deputy Managing Director Sharvil Patel told the news service.

Cadila has no plans to stop there. It's already scheduled meetings with regulators in the U.S. and EU, where Humira will lose patent protection in 2016 and 2018, respectively, Patel said. "We are working towards being among the first wave of the launch of this drug's biosimilars globally," he said, noting that Humira has "a very attractive market."
 




Anonymous said:
Sales revenue may last a bit longer but sales reps will not. Don't delude yourself.
Click to expand...

Amgen announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.
 




Anonymous said:
Amgen announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.
Click to expand...



Amgen just went through a wave of hiring for their new PCSK9 inhibitor.
 
































Similar threads

Humira is the money engine
Replies
10
Views
4K
AbbVie
anonymous
Goodbye Humira, hello Biosimilars
Replies
12
Views
4K
AbbVie
anonymous
Milking Humira!!!
Replies
10
Views
4K
AbbVie
anonymous
Abbvie going to pit humira reps against upa.
Replies
7
Views
4K
AbbVie
anonymous
Competitors hiring humira reps.
Replies
30
Views
7K
AbbVie
anonymous
Top Bottom
Back
Quote